Home - Products - Cell Cycle/DNA Damage - DNA/RNA Synthesis - Thiostrepton

Thiostrepton

CAS No. 1393-48-2

Thiostrepton ( Bryamycin; NSC 81722; NSC 170365; Thiactin; Thiostreptin A )

Catalog No. M11641 CAS No. 1393-48-2

Thiostrepton is a one of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria.

Purity : >98%(HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
25MG	27	In Stock
50MG	35	In Stock
100MG	50	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Thiostrepton
Note

Research use only, not for human use.
Brief Description

Thiostrepton is a one of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria.
Description

Thiostrepton is a one of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders.
Synonyms

Bryamycin; NSC 81722; NSC 170365; Thiactin; Thiostreptin A
Pathway

Cell Cycle/DNA Damage
Target

DNA/RNA Synthesis
Recptor

DNA synthesis
Research Area

Infection
Indication

——

Chemical Information

CAS Number

1393-48-2
Formula Weight

1664.89
Molecular Formula

C72H85N19O18S5
Purity

>98%(HPLC)
Solubility

DMSO: 40mg/mL
SMILES

NC[S=N]H(C)C(O)=O
Chemical Name

Thiostrepton

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Kuiper EG, Conn GL. J Biol Chem. 2014 Sep 19;289(38):26189-200.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

CCG-203971

CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.
JH-RE-06

JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
T2AA

T2AA is an inhibitor of proliferating cell nuclear antigen (PCNA) with IC50 of 1 μM for PCNA/PIP-box peptide interaction.

Sign In Join Free